Due to a drug developed in collaboration with AstraZeneca failing to achieve its primary endpoint in a late-stage clinical trial for heart disease, shares of Ionis Pharmaceuticals, Inc. plummeted 13.8% in pre-market trading.

Due to a drug developed in collaboration with AstraZeneca failing to achieve its primary endpoint in a late-stage clinical trial for heart disease, shares of Ionis Pharmaceuticals, Inc. plummeted 13.8% in pre-market trading.

老虎证券2026/07/09 08:51

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This setback in the clinical trial significantly dampened market expectations regarding the drug's prospects, prompting investors to swiftly sell off shares. The sharp fluctuation in share price reflects the market's heightened sensitivity to the progress of biopharmaceutical companies' research and development pipelines, especially when key late-stage trial results are announced.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Due to a drug developed in collaboration with AstraZeneca failing to achieve its primary endpoint in a late-stage clinical trial for heart disease, shares of Ionis Pharmaceuticals, Inc. plummeted 13.8% in pre-market trading.

You may also like

Crypto prices